Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer (CREST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04165317
Recruitment Status : Recruiting
First Posted : November 15, 2019
Last Update Posted : July 25, 2022
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:

The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk (Part A) or was previously treated with BCG (Bacillus Calmette Guerin), a standard treatment for bladder cancer (Part B).

In Part A (enrollment closed), each participant was assigned to one of three study treatment groups.

  • One group is given sasanlimab and BCG at the study clinic.
  • The second group is given sasanlimab and BCG at the study clinic. This group will receive BCG for the first six weeks only.
  • The third group is given BCG only and will not receive sasanlimab.

In Part B of the study, each new participant will be assigned to a study treatment group based on the type of their bladder tumor.

- Both groups will be given sasanlimab at the study clinic.


Condition or disease Intervention/treatment Phase
Non-muscle Invasive Bladder Cancer Drug: PF-06801591 Drug: Bacillus Calmette-Guerin Phase 3

Detailed Description:

CREST: Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with Subcutaneous anti-PD-1 Treatment

Phase 3 Design with two Cohorts. Cohort A consists of 3 study Arms (A, B and C) of BCG naive participants. Arms A and B consist of two study drugs, PF-06801591 plus BCG. Arm C consists of one study drug, BCG. Cohort B consists of B1 and B2, which test PF-06801591 and include participants who have BCG unresponsive CIS (B1) or BCG unresponsive papillary only disease (B2).

The study is designed to demonstrate that PF-06801591 plus Bacillus Calmette Guerin (BCG) (induction and maintenance periods) is superior to BCG alone (induction and maintenance periods) in prolonging event free survival (EFS) in participants with high-risk naïve non-muscle invasive bladder cancer (NMIBC) and to demonstrate that PF-06801591 plus BCG (induction period only) is superior to BCG alone (induction and maintenance periods) in prolonging EFS in participants with high-risk NMIBC. The study is also designed to estimate the CR rate of PF-06801591 alone in participants with BCG unresponsive CIS and to evaluate the EFS of PF-06801591 alone in participants with BCG unresponsive NMIBC.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 Antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants With High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer or PF-06801591 as a Single Agent in Participants With BCG-Unresponsive NMIBC
Actual Study Start Date : December 30, 2019
Estimated Primary Completion Date : June 3, 2024
Estimated Study Completion Date : August 8, 2028

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Arm Intervention/treatment
Experimental: PF-06801591 + BCG induction and maintenance
PF-06801591 in combination with Bacillus Calmette Guerin(induction+maintenance).
Drug: PF-06801591
A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
Other Name: Sasanlimab

Drug: Bacillus Calmette-Guerin
Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
Other Name: BCG

Experimental: PF-06801591 + BCG induction only
PF-06801591 in combination with Bacillus Calmette Guerin (induction only).
Drug: PF-06801591
A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
Other Name: Sasanlimab

Drug: Bacillus Calmette-Guerin
Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
Other Name: BCG

Active Comparator: BCG induction and maintenance
Bacillus Calmette Guerin (induction and maintenance).
Drug: Bacillus Calmette-Guerin
Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
Other Name: BCG

Experimental: BCG Unresponsive CIS
PF-06801591
Drug: PF-06801591
A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
Other Name: Sasanlimab

Experimental: BCG Unresponsive NMIBC
PF-06801591
Drug: PF-06801591
A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
Other Name: Sasanlimab




Primary Outcome Measures :
  1. Event free survival (Cohort A: Arm A compared to Arm C) [ Time Frame: 55 months after first participant randomized ]
    Event free survival is defined as the time from randomization to date of EFS event.

  2. Event free survival (Cohort A: Arm B compared to Arm C) [ Time Frame: 55 months after first participant randomized ]
    Event free survival is defined as the time from randomization to date of EFS event.

  3. Complete response rate (Cohort B1) [ Time Frame: Registration to 12 months after last participant initially assessed ]
    Complete response (CR) rate defined as the proportion of participants in the analysis population with CR.

  4. Event free survival (Cohort B2) [ Time Frame: Registration to 12 months after last participant initially assessed ]
    Event free survival is defined as the time from first dose to date of EFS event.


Secondary Outcome Measures :
  1. Overall Survival (Cohort A: Arm A compared to Arm C) [ Time Frame: Randomization up to 60 months from last participant randomized ]
    Overall survival is defined as the time from the date of randomization to the date of death due to any cause.

  2. Overall Survival (Cohort A: Arm B compared to Arm C) [ Time Frame: Randomization up to 60 months from last participant randomized ]
    Overall survival is defined as the time from the date of randomization to the date of death due to any cause.

  3. Complete response rate in participants with CIS at randomization (Cohort A: Arm A, B, C) [ Time Frame: Randomization up to 60 months from last participant randomized ]
    Complete response (CR) rate defined as the proportion of participants in the analysis population with CR.

  4. Disease-specific survival (Cohort A: Arm A, B, C) [ Time Frame: Randomization up to 60 months from last participant randomized ]
    Disease specific survival (DSS) is defined as the time from randomization to death resulting from bladder cancer.

  5. Health-related quality of life as measured by EORTC QLQ-C30 (European Organization for Treatment of Cancer Quality of Life Questionnaire for cancer patients) [ Time Frame: Randomization up to 60 months from last participant randomized ]
    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties).

  6. ctrough of PF-06801591 when in combination with BCG (induction and maintenance or induction). Cohort A: Arms A and B only. [ Time Frame: Randomization up to 24 months ]
    Ctrough will be summarized in Cohort A Arms A and B only.

  7. Incidence of ADA/Nab of PF-06801591 when in combination with BCG (induction and maintenance or induction). Cohort A: Arms A and B only. [ Time Frame: Randomization up to 24 months ]
    Immunogenicity will be evaluated for Cohort A Arms A and B only.

  8. Tumor sample biomarker status based on PD-L1 expression (high or low) [ Time Frame: Baseline ]
    Evaluate PD-L1 expression.

  9. Duration of CR for participants with CIS at randomization [ Time Frame: Randomization/registration up to 60 months from last participant randomized ]
    Duration of CR is defined as time from first CR to first recurrence or death due to any cause, whichever occurs first.

  10. Time to recurrence of low grade disease (Cohort A: Arm A, B, C) [ Time Frame: Randomization up to 60 months from last participant randomized ]
    Time to recurrence defined as time from randomization to the date of first documentation of recurrence of low grade disease or death due to any cause, whichever occurs first.

  11. Time to cystectomy [ Time Frame: Randomization/registration to date of cystectomy (up to 5 years after last participant is randomized) ]
    Time to cystectomy is defined as time from randomization/registration to cystectomy in participants with NMIBC

  12. Health-related quality of life as measured by PTAB (Patient Treatment Administration Burden Questionnaire) [ Time Frame: Randomization/registration up to 24 months ]
    PTAB is a 2-item PRO designed to assess, from the patient perspective, any pain associated with the treatment administration and the burden of the amount of time required to complete the treatment administration procedures (1 item each).

  13. Percentage of Participants With All Causality and Treatment-related Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs [ Time Frame: Baseline up to 60 months from the last participant randomized ]
    An adverse event (AE) is any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs comprised both SAEs and non-SAEs. Causality assessment is made by the investigator. Grading is per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) version 3.0.

  14. Percentage of Participants With Laboratory Abnormalities [ Time Frame: Baseline up to 60 months from last participant randomized ]
    Percentage of participants with laboratory test abnormalities without regard to baseline abnormality. Grading is per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) version 3.0.

  15. Health-related quality of life as measured by EORTC QLQ-NMIBC24 (European Organization for Treatment of Cancer in patients with non-muscle invasion bladder cancer) [ Time Frame: Randomization/registration up to 60 months from the last participant randomized ]
    EORTC-QLQ-NMIBC24 has 24 items which can be grouped into 6 subscales: urinary symptoms (7 items), malaise (2 items), future worries (4 items), bloating/flatulence (2 items), sexual functioning (2 items), and male sexual issues (2 items). The NMIBC24 also assesses intravesical treatment, female sexual issues, sexual intimacy, risk of contaminating a partner, and sexual enjoyment (1 item each).

  16. Complete response rate at 12 months (Cohort B1) [ Time Frame: 12 months after last participant's initial assessment ]
    Complete response (CR) rate defined as the proportion of participants in the analysis population with CR at 12 months.

  17. Event Free Survival (Cohort B1) [ Time Frame: Registration to 5 years after last participant randomized. ]
    Time from first dose to date of EFS event.

  18. Overall Survival (Cohorts B1 and B2) [ Time Frame: Registration to 5 years after last participant randomized. ]
    Time from the date of first dose to the date of death due to any cause.

  19. ctrough of PF-06801591 (Cohorts B1 and B2) [ Time Frame: Registration up to 24 months ]
    Ctrough will be summarized

  20. Incidence of ADA/Nab of PF-06801591 (Cohorts B1 and B2) [ Time Frame: Registration up to 24 months ]
    Immunogenicity will be evaluated for participants with BCG unresponsive NMIBC, including those with CIS.

  21. cmax of PF-06801591 (Cohort B2 only) [ Time Frame: Registration up to 24 months ]
    Cmax will be summarized in Cohort B2 only.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histological confirmed diagnosis of high risk non-muscle invasive transitional cell carcinoma (TCC) of the urothelium of the urinary bladder (tumors of mixed transitional/non-transitional cell histology are allowed, but TCC must be the predominant histology)
  • Complete resection of all Ta/T1 papillary disease (including participants with concurrent CIS), with most recent positive TURBT occurring within 12 weeks prior to randomization or study intervention. A second TURBT must have been performed if indicated according to the current locally applicable guidelines, ie, American Urological Association, European Association of Urology
  • (Cohorts B1 and B2 only): Histological confirmed diagnosis of BCG-unresponsive high-risk, non-muscle invasive TCC of the urothelium within 12 months (CIS only) or 6 months (recurrent Ta/T1 disease) of completion of adequate BCG therapy.
  • Have refused or are ineligible for radical cystectomy

Exclusion Criteria:

  • Evidence of muscle-invasive, locally advanced or metastatic urothelial cancer or concurrent extravesical, non-muscle invasive TCC of the urothelium
  • (Cohort A only): Intravesical BCG therapy within 2 years prior to randomization. Prior intravesical chemotherapy for NMIBC is allowed.

(Cohorts B1 and B2 only): Any systemic or intravesical chemotherapy or immunotherapy from the time of most recent positive TURBT to initiation of study intervention.

  • Prior immunotherapy with anti PD-1, anti PD-L1, anti PD-L2, or anti cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody
  • Prior treatment with immunostimulatory agents including interleukin (IL)-2, IL-15, interferon (INF)
  • Prior radiation therapy to the bladder
  • (Cohorts B1 and B2 only): Prior participation in Cohort A of this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04165317


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Locations
Show Show 194 study locations
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT04165317    
Other Study ID Numbers: B8011006
2019-003375-19 ( EudraCT Number )
First Posted: November 15, 2019    Key Record Dates
Last Update Posted: July 25, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
CREST
Sasanlimab
PF-06801591
Bacillus Calmette Guerin
BCG
Bladder cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
BCG Vaccine
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs